⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
India carries 26% of the global tuberculosis (TB) burden — approximately 2.8 million new TB cases are diagnosed annually, and an estimated 40% of the Indian population has latent TB infection. For people with type 2 diabetes or obesity who are on GLP-1 medications, TB represents an especially important consideration: diabetes triples the risk of TB activation, and the nutritional changes caused by GLP-1 therapy can further affect how the body fights infection. This guide is designed for Indian patients on semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro) who have been diagnosed with active TB, are being treated for latent TB, or are concerned about TB risk.
Consult your healthcare provider before starting any medication or if you have TB-related concerns.
The relationship between metabolic disease and tuberculosis is bidirectional and well-established:
Diabetes increases TB risk 3-fold. Hyperglycaemia impairs several key immune mechanisms: neutrophil function is reduced, macrophage killing of Mycobacterium tuberculosis is impaired, and T-cell responses are blunted. Indian data from ICMR-partnered studies shows that TB patients with diabetes have worse outcomes — higher mortality, more treatment failure, and greater risk of multidrug-resistant TB (MDR-TB) — than TB patients without diabetes.
Obesity creates immune dysregulation. Adipose tissue secretes pro-inflammatory cytokines (TNF-alpha, IL-6) that can paradoxically suppress the specific cell-mediated immune response required to contain latent TB. Rapid weight loss — as occurs with GLP-1 therapy — can temporarily alter this inflammatory milieu in complex ways.
GLP-1 therapy improves glycaemic control, which should theoretically reduce TB risk. Better glycaemic control has been associated with improved TB treatment outcomes in diabetic patients. This is one area where GLP-1 therapy may offer indirect protection.
This is the most clinically critical section for anyone on both GLP-1 therapy and anti-TB treatment.
Rifampicin (rifampin) is the backbone of standard first-line TB treatment (HRZE: isoniazid, rifampicin, pyrazinamide, ethambutol). Rifampicin is one of the most potent inducers of hepatic cytochrome P450 enzymes (particularly CYP3A4, CYP2C9) known in clinical medicine.
Does rifampicin affect semaglutide or tirzepatide?
Semaglutide and tirzepatide are large peptide molecules. They are not primarily metabolised by CYP enzymes — they are broken down by general proteolytic pathways and eliminated primarily through renal and proteolytic mechanisms. Therefore, rifampicin's CYP-induction effect is not expected to significantly alter semaglutide or tirzepatide blood levels.
However, there is an important indirect consideration: rifampicin causes significant nausea in many patients. Combined with GLP-1-induced nausea (especially in early treatment), patients may experience compounding gastrointestinal symptoms. This can lead to undernutrition during TB treatment — already a serious concern.
Practical guidance: Discuss with both your TB physician and your prescribing doctor. The timing of GLP-1 dose escalation may need to be slowed during TB treatment initiation to avoid compounding nausea.
Isoniazid can cause peripheral neuropathy (numbness and tingling in hands and feet) by depleting pyridoxine (vitamin B6). Patients on GLP-1 therapy who are also experiencing reduced food intake may have lower baseline B6 levels. Pyridoxine supplementation (10–25 mg/day) is routinely given with isoniazid in India — this is especially important for GLP-1 users.
GLP-1 therapy has been associated in some cases with numbness and tingling (numbness-tingling side effect), separate from isoniazid neuropathy. If you develop numbness or tingling on both medications, alert both your doctors — distinguishing drug-induced neuropathy from diabetic neuropathy from isoniazid neuropathy requires clinical assessment.
Pyrazinamide (PZA) elevates uric acid levels and can precipitate gout. GLP-1 medications have been associated with changes in uric acid levels during rapid weight loss — a complex and bidirectional effect. If you have a history of gout or hyperuricaemia, inform both your TB physician and GLP-1 prescriber. Monitor uric acid during the initial 2-month intensive phase of TB treatment.
For multidrug-resistant TB (MDR-TB), fluoroquinolones (levofloxacin, moxifloxacin) are commonly used in India. These may affect blood sugar levels — fluoroquinolones can cause both hypoglycaemia and hyperglycaemia. If you are on a GLP-1 medication plus insulin or a sulphonylurea, be especially vigilant about blood sugar monitoring during fluoroquinolone-based MDR-TB therapy.
TB treatment places enormous nutritional demands on the body. GLP-1 therapy suppresses appetite. This combination can lead to dangerous undernutrition:
During TB treatment on GLP-1, the priority shifts from weight loss to nutritional adequacy. Weight loss may need to be paused. Discuss with your doctors whether to hold GLP-1 dose escalation and focus entirely on maintaining adequate protein and caloric intake.
| Nutrient | Daily Target | Indian Food Sources |
|---|---|---|
| Protein | 1.2–1.5g per kg body weight | Eggs, dal, paneer, chicken, curd |
| Calories | At or above TDEE (not deficit) | Increase frequency, not just portion size |
| Vitamin B6 | 25–50mg (take with INH) | Supplement + banana, potato |
| Vitamin D | 1000–2000 IU | Supplement (India's TB patients commonly deficient) |
| Zinc | 15–20mg | Supplement or increase nuts, seeds, legumes |
| Iron | As needed (check CBC) | Fortified foods, supplementation if anaemic |
Indian guidelines recommend TB screening for all diabetic patients because of the significantly elevated risk. The standard tests are:
Mantoux test (PPD/TST): An intradermal injection of tuberculin is read at 48–72 hours. A reaction ≥10 mm is considered positive in diabetic patients (lower threshold than immunocompetent individuals). Widely available in India at government hospitals.
IGRA (Interferon Gamma Release Assay): QuantiFERON-Gold or T-SPOT TB. More specific than Mantoux; not affected by BCG vaccination. More expensive, available at large private labs (SRL, Metropolis, Thyrocare).
If you have:
...then TB screening is appropriate. Discuss with your doctor.
TB can be harder to recognise in someone on GLP-1 therapy because some symptoms overlap:
| Symptom | TB Cause | GLP-1 Overlap |
|---|---|---|
| Weight loss | TB catabolism | Intentional GLP-1 effect |
| Reduced appetite | TB constitutional effect | GLP-1 effect |
| Fatigue | TB systemic effect | Early GLP-1 effect |
| Nausea | TB treatment drugs | GLP-1 effect |
TB-specific symptoms that are NOT caused by GLP-1:
If you have any TB-specific symptoms, seek medical evaluation promptly — do not attribute them to GLP-1.
Standard first-line TB treatment in India follows the RNTCP/National TB Elimination Programme (NTEP) protocol:
During this 6-month period, if you are on GLP-1 therapy, you should have more frequent monitoring than usual:
After completing TB treatment, many Indian patients are left with residual lung changes, reduced lung capacity, and muscle weakness from the 6 months of illness. GLP-1 therapy can resume its standard role in weight and metabolic management at this point.
Key post-TB nutritional priorities before resuming aggressive caloric restriction on GLP-1:
Q: I'm starting TB treatment and am on Ozempic. Should I stop Ozempic?
Do not stop without consulting your doctor. Many patients can continue GLP-1 therapy through TB treatment with appropriate nutritional monitoring and possibly holding dose escalation. The decision depends on your weight, nutritional status, and glycaemic control needs.
Q: Can GLP-1 therapy help me fight TB better?
Indirectly, yes — improved glycaemic control is associated with better TB treatment outcomes. This is an active area of research. However, GLP-1 medications do not have direct antimycobacterial properties.
Q: I had TB 5 years ago. Can I now take Ozempic or Mounjaro?
Yes, successfully treated TB is not a contraindication to GLP-1 therapy. Inform your prescribing doctor of your TB history. A baseline chest X-ray is a reasonable precaution.
Q: I live in a joint family and a family member has TB. I'm on Mounjaro. What precautions should I take?
Standard TB infection control: the TB patient should wear a mask, rooms should be well-ventilated, and you should discuss TB screening (Mantoux or IGRA) with your doctor given your diabetic status and GLP-1 therapy. Do not stop your Mounjaro based on household exposure alone.
